EUVIMEDDescoperă EUVIMED
Crossref

Liquid Biopsy in Precision Oncology: Expanding Clinical Applications for Molecular Characterization, Disease Monitoring, and Personalized Management of Solid Tumors

Ricardo Fernando Rincón Veloz, Ana Milena Murgas Acevedo, Gerardo Amaya Villagran, Mena Acosta Byron Hernán, Dominique Isaac Nuñez Gonzalez, Joseph Rodríguez Sánchez, Alexa Fernanda Uriostegui Navarro, Jorge Angel Velasco Espinal

International Science Journal · 2026-07-31 · 4 (2)

DOI: 10.64784/272 ↗

At a glance

Journal article in International Science Journal, published online on 2026-07-31. Written by Ricardo Fernando Rincón Veloz and 7 co-authors.

RezumatDate bibliograficeCiteRelated studies

Abstract (original language)

Liquid biopsy has rapidly emerged as one of the most promising innovations in precision oncology by providing minimally invasive access to tumor-derived biomarkers throughout the clinical course of cancer. This review analyzes the current evidence regarding the clinical applications of liquid biopsy beyond early cancer detection, emphasizing its role in molecular profiling, therapeutic selection, treatment monitoring, minimal residual disease assessment, identification of resistance mechanisms, and evaluation of tumor heterogeneity in patients with solid tumors. A comprehensive literature review was conducted using major biomedical databases, selecting high-quality publications focused on circulating tumor DNA, circulating tumor cells, extracellular vesicles, circulating RNA, and other emerging biomarkers. The available evidence demonstrates that circulating tumor DNA currently represents the most clinically validated biomarker because of its high analytical performance and increasing incorporation into precision oncology protocols. Liquid biopsy has shown particular utility in lung, colorectal, breast, and prostate cancers, where molecular information directly contributes to personalized treatment decisions. Nevertheless, several barriers continue to limit universal implementation, including high costs, limited molecular infrastructure, methodological variability, and unequal access to advanced genomic technologies, particularly in developing countries. Ongoing technological improvements, international collaboration, and methodological standardization are expected to further expand the clinical applications of liquid biopsy and facilitate its incorporation into routine oncology practice. Overall, liquid biopsy represents a transformative strategy that complements conventional tissue biopsy and supports more personalized, dynamic, and evidence-based management of solid tumors.

Cite

APA

Veloz, R. F. R., Acevedo, A. M. M., Villagran, G. A., Hernán, M. A. B., Gonzalez, D. I. N., Sánchez, J. R., Navarro, A. F. U., & Espinal, J. A. V. (2026). Liquid Biopsy in Precision Oncology: Expanding Clinical Applications for Molecular Characterization, Disease Monitoring, and Personalized Management of Solid Tumors. International Science Journal, 4(2). https://doi.org/10.64784/272

Vancouver

Veloz RFR, Acevedo AMM, Villagran GA, Hernán MAB, Gonzalez DIN, Sánchez JR, et al. Liquid Biopsy in Precision Oncology: Expanding Clinical Applications for Molecular Characterization, Disease Monitoring, and Personalized Management of Solid Tumors. International Science Journal. 2026;4(2). doi:10.64784/272

BibTeX
@article{Veloz2026,
  author = {Veloz, Ricardo Fernando Rincón and Acevedo, Ana Milena Murgas and Villagran, Gerardo Amaya and Hernán, Mena Acosta Byron and Gonzalez, Dominique Isaac Nuñez and Sánchez, Joseph Rodríguez and Navarro, Alexa Fernanda Uriostegui and Espinal, Jorge Angel Velasco},
  title = {Liquid Biopsy in Precision Oncology: Expanding Clinical Applications for Molecular Characterization, Disease Monitoring, and Personalized Management of Solid Tumors},
  journal = {International Science Journal},
  year = {2026},
  volume = {4},
  number = {2},
  doi = {10.64784/272}
}
Start for free →